Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Less than 24 hours after the onset of MI symptoms~* ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads~* Myocardial necrosis, as evidenced by increased CK-MB and troponin levels~Exclusion Criteria:~* Use of statins for at least 6 months prior the myocardial infarction

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- No lipid-lowering (Type: NO_INTERVENTION): No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
- Simvastatin 20 mg (Type: EXPERIMENTAL): Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
- Simvastatin 40 mg (Type: EXPERIMENTAL): Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
- Simvastatin 80 mg (Type: EXPERIMENTAL): Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).